Lacosamide Aurovitas 150 mg film-coated tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Lacosamida Aurovitas 150 mg film-coated tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents:

1. What Lacosamida Aurovitas is and what it is used for
2. What you need to know before taking Lacosamida Aurovitas
3. How to take Lacosamida Aurovitas
4. Possible adverse effects
5. How to store Lacosamida Aurovitas
6. Contents of the pack and other information

1. What Lacosamida Aurovitas is and what it is used for

What is Lacosamida

This medicine contains lacosamida, which belongs to a group of medicines called
"antiepileptic medicines". These medicines are used to treat epilepsy.

• You have been prescribed this medicine to reduce the number of seizures you experience.

What lacosamida is used for

• Lacosamida is used:

  • as monotherapy and in combination with other antiepileptic medicines in adults, adolescents, and children from 2 years of age, to treat a certain type of epilepsy characterized by partial-onset seizures with or without secondary generalization. In this type of epilepsy, seizures affect only one side of the brain. However, they may then spread to larger areas on both sides of the brain;

  • in combination with other antiepileptic medicines in adults, adolescents, and children from 4 years of age, to treat primary generalized tonic-clonic seizures (major seizures, with loss of consciousness) in patients with idiopathic generalized epilepsy (a type of epilepsy believed to have a genetic origin).

2. What you need to know before taking Lacosamida Aurovitas

Do not take Lacosamida Aurovitas

• if you are allergic to lacosamide or to any of the other ingredients of this medicine

(listed in section 6). If you are unsure whether you are allergic, consult your doctor

• if you are allergic to peanuts or soya
• if you have a heart rhythm problem called second- or third-degree AV block.

Do not take this medicine if any of the above apply to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medicine:

• if you have thoughts of self-harm or suicide. A small number of people being treated

with antiepileptic medicines such as lacosamide have had thoughts of self-harm or suicide. If

you have such thoughts at any time, contact your doctor immediately.

• if you have a heart condition affecting your heartbeat and your pulse is often

particularly slow, fast, or irregular (such as AV block, atrial fibrillation, or atrial flutter).

• if you have severe heart disease such as heart failure or have had a myocardial

infarction.

• if you feel dizzy or fall frequently. Lacosamide may cause dizziness, which could increase the risk of accidental injury or falls. This means you should be cautious until you are accustomed to the effects of this medicine.

If any of the above apply to you (or you are unsure), consult your doctor or pharmacist before taking this medicine.

If you are taking Lacosamida, consult your doctor if you experience a new type of seizure or worsening of existing seizures.

If you are taking this medicine and experience symptoms of abnormal heartbeat (such as slow, fast, or irregular heartbeat, palpitations, dyspnea (difficulty breathing), dizziness, or fainting), consult your doctor immediately (see section 4).

Children

Lacosamide is not recommended in children under 2 years of age with epilepsy characterized by partial-onset seizures, and is not recommended for children under 4 years of age with primary generalized tonic-clonic seizures. This is because it is not yet known whether it is effective and safe in children of this age group.

Other medicines and Lacosamida Aurovitas

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

In particular, inform your doctor or pharmacist if you are taking any of the following medicines that affect the heart, as lacosamide may also affect the heart:

• medicines used to treat heart problems;

• medicines that may increase the "PR interval" in a heart test (ECG or electrocardiogram), such as medicines for epilepsy or pain called carbamazepine, lamotrigine, or pregabalin;

• medicines used to treat certain types of arrhythmia or heart failure.

If any of the above apply to you (or you are unsure), speak with your doctor or pharmacist before taking this medicine.

Also inform your doctor or pharmacist if you are taking any of the following medicines, as they may increase or decrease the effect of lacosamide in your body:

• antifungal medicines such as fluconazole, itraconazole, or ketoconazole;
• an HIV medicine such as ritonavir;
• antibacterial medicines such as clarithromycin or rifampicin;
• a herbal remedy used to treat mild anxiety and depression called St. John's wort.

If any of the above apply to you (or you are unsure), speak with your doctor or pharmacist before taking lacosamide.

Taking Lacosamida Aurovitas with alcohol

As a safety precaution, do not take this medicine with alcohol.

Pregnancy and breastfeeding

Women of childbearing potential should discuss the use of contraception with their doctor.

If you are pregnant or breastfeeding, think you might be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Lacosamide is not recommended during pregnancy, as the effects of this medicine on pregnancy and the fetus are not known.

Breastfeeding is not recommended while taking lacosamide, as it passes into breast milk. Seek immediate advice from your doctor if you are pregnant or planning to become pregnant. They will help you decide whether you should take lacosamide.

Do not stop treatment without first talking to your doctor, as this could increase seizures. Worsening of your condition may also harm the fetus.

Driving and using machines

You must not drive, ride a bicycle, or operate any tools or machinery until you know how this medicine affects you. The reason is that lacosamide may cause dizziness or blurred vision.

Lacosamida Aurovitas contains soya lecithin

If you are allergic to peanuts or soya, do not take this medicine.

3. How to take Lacosamida Aurovitas

Follow exactly the instructions for administration of this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again. Another form(s) of this medicine may be more suitable for children; consult your doctor or pharmacist.

Taking Lacosamida

• Take lacosamida twice daily, at approximately 12-hour intervals.
• Try to take it at about the same time each day.
• Swallow the lacosamida tablet with a glass of water.
• You may take lacosamida with food or separately.

Usually, you will start with a low daily dose, and your doctor will gradually increase the dose over several weeks. When you reach the dose that works well for you, called the “maintenance dose”, you will take the same amount every day. Lacosamida is used as a long-term treatment. You should continue taking lacosamida until your doctor tells you to stop.

What dose to take

Below are the recommended normal doses of lacosamida for different age and weight groups. Your doctor may prescribe a different dose if you have kidney or liver problems.

Adolescents and children weighing 50 kg or more, and adults

When taking lacosamida alone:

The usual starting dose is 50 mg twice daily.

Your doctor may also prescribe a starting dose of 100 mg of lacosamida twice daily. Your doctor may increase your twice-daily dose by 50 mg each week, until reaching a maintenance dose between 100 mg and 300 mg twice daily.

When taking lacosamida with other antiepileptic medicines:

The usual starting dose is 50 mg twice daily.

Your doctor may increase your twice-daily dose by 50 mg each week, until reaching a maintenance dose between 100 mg and 200 mg twice daily.

If you weigh 50 kg or more, your doctor may start lacosamida treatment with a single “loading” dose of 200 mg. Then you would start taking the regular maintenance dose 12 hours later.

Children and adolescents weighing less than 50 kg

• In the treatment of partial-onset seizures: Note that lacosamida is not recommended for children under 2 years of age.
• In the treatment of primary generalized tonic-clonic seizures: Note that lacosamida is not recommended for children under 4 years of age.

The dose depends on body weight. Treatment is usually started with the oral syrup, and only switched to tablets if the patient is able to swallow them and can achieve the correct dose using tablets of different strengths. Your doctor will prescribe the pharmaceutical form best suited to you.

If you take more lacosamida than you should

If you have taken more lacosamida than you should, contact your doctor immediately. Do not attempt to drive.

You may experience:

• dizziness;
• feeling sick (nausea) or being sick (vomiting);
• seizures, heart rhythm problems such as slow, fast or irregular pulse, coma, or low blood pressure with tachycardia and sweating.

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at: 91 562 04 20, stating the medicine and the amount ingested.

If you forget to take lacosamida

• If you forget to take a dose within 6 hours of the scheduled time, take it as soon as you remember.

• If you forget to take a dose more than 6 hours after the scheduled time, do not take the missed dose; instead, take lacosamida at the next scheduled time.

• Do not take a double dose to make up for a forgotten dose.

If you stop taking lacosamida

• Do not stop taking lacosamida without telling your doctor, as epilepsy may return or worsen.
• If your doctor decides to stop your lacosamida treatment, you will be given instructions on how to gradually reduce the dose.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, lacosamide may cause adverse effects, although not everyone experiences them.

Nervous system effects, such as dizziness, may be greater after a single "loading" dose.

Tell your doctor or pharmacist if you experience any of the following effects:

Very common: may affect more than 1 in 10 patients

• Headache;
• Feeling dizzy or sick (nausea);
• Double vision (diplopia).

Common: may affect up to 1 in 10 patients

• Brief jerks of a muscle or group of muscles (myoclonic seizures);
• Difficulty coordinating movements or walking;
• Problems maintaining balance, tremor, tingling (paraesthesia), or muscle spasms, tendency to fall and bruise easily;
• Memory problems, difficulty thinking or finding words, confusion;
• Rapid, uncontrolled eye movements (nystagmus), blurred vision;
• Feeling of dizziness (vertigo), sensation of drunkenness;
• Dizziness (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or intestines, diarrhoea;
• Decreased sensation, difficulty speaking, attention disturbance;
• Ringing in the ears such as buzzing, ringing, or whistling;
• Irritability, sleep problems, depression;
• Drowsiness, fatigue or weakness (asthenia);
• Itching, rash.

Uncommon: may affect up to 1 in 100 patients

• Decreased heart rate, palpitations, irregular pulse, or other changes in the heart's electrical activity (conduction disorder);
• Exaggerated feeling of well-being, seeing and/or hearing things that are not real;
• Allergic reaction to the medicine, hives;
• Blood tests may show abnormalities in liver function tests, liver damage;
• Thoughts of self-harm or suicide, or suicide attempt: inform your doctor immediately;
• Feeling angry or agitated;
• Abnormal thoughts or loss of sense of reality;
• Severe allergic reactions causing swelling of the face, throat, hands, feet, ankles, or lower legs;
• Fainting;
• Abnormal involuntary movements (dyskinesia).

Frequency not known: cannot be estimated from available data

• Abnormally fast heartbeat (ventricular tachyarrhythmia);
• Sore throat, high temperature, and increased frequency of infections. Blood tests may show a severe decrease in a specific type of white blood cells (agranulocytosis);
• Serious skin reaction, which may include high temperature and other flu-like symptoms, rash on the face, widespread rash with swollen glands (enlarged lymph nodes). Blood tests may show increased liver enzyme levels and an increase in a type of white blood cells (eosinophilia);
• Widespread rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling over more than 30% of the body surface (toxic epidermal necrolysis);
• Seizures.

Other adverse effects in children

Additional adverse effects observed in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), eating less than usual (decreased appetite), behavioural changes, not acting as they normally do (abnormal behaviour), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.

Reporting of adverse effects

If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines website: www.notificaRAM.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Lacosamide Aurovitas

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton and blister after EXP/CAD. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their packaging at a pharmacy’s SIGRE point. If you have any doubts, ask your pharmacist how to properly dispose of medicines and packaging you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Lacosamida Aurovitas 150 mg film-coated tablets EFG

• The active substance is lacosamide. Each film-coated tablet contains 150 mg of lacosamide.
• The other components are:

Tablet core: Microcrystalline cellulose (Grade-101), low-substituted hydroxypropylcellulose, crospovidone (type A), hydroxypropylcellulose, microcrystalline cellulose (Grade-102), colloidal anhydrous silica, magnesium stearate.

Tablet coating: Titanium dioxide (E171), hypromellose (6 mPa·s) (E464), talc (E553b), poly(vinyl alcohol) (E1203), hypromellose (15 mPa·s) (E464), macrogol 3350 (E1521), soya lecithin (E322), red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172).

Appearance of the product and contents of the pack

Film-coated tablet.

Light orange to pink-orange, oval-shaped film-coated tablets (size 15.1 x 7.0 mm), marked with "150" on one side and "L" and "A" on either side of the score line on the other side. The tablet can be divided into equal doses.

Lacosamida Aurovitas 150 mg film-coated tablets EFG are available in blister packs.

Pack sizes:

Blister packs: 14, 28, 56, 168 film-coated tablets and multiple packs containing 168 tablets (3 packs of 56 film-coated tablets).

Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Manufacturer

APL Swift Services (Malta) Limited

HF26, Hal Far Industrial Estate, Hal Far

Birzebbugia, BBG 3000

Malta

Or

Generis Farmacêutica, S.A.

Rua João de Deus, 19

2700-487 Amadora

Portugal

This medicinal product is authorized in the European Economic Area member states under the following names:

France: Lacosamide Arrow 150 mg comprimé pelliculé

Germany: Lacosamid PUREN 150 mg Filmtabletten

Italy: Lacosamide Aurobindo

Portugal: Lacosamida Generis

Spain: Lacosamida Aurovitas 150 mg comprimidos recubiertos con película EFG

Date of the most recent review of this leaflet: February 2023

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).